NCT01459887View on ClinicalTrials.gov

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL

Enrollment

278

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

CHOP combined with CMAB304

Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.

DRUG

CHOP, CMAB304

First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.

Trial Locations (1)

510060

SUN-YAT-SEN university cancer center, Guangzhou

All Listed Sponsors

lead

Shanghai CP Guojian Pharmaceutical Co., Ltd.

INDUSTRY

NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter